igarette smoking constitutes a major health hazard contributing significantly to cardiovascular morbidity and mortality. The effects of smoking on the pharmacokinetics and pharmacodynamics of clopidogrel have been the subject of numerous reports over the last decade (Table 1) (1-24). The data on the association of smoking and platelet responsiveness to adenosine diphosphate- 
C igarette smoking constitutes a major health hazard contributing significantly to cardiovascular morbidity and mortality. The effects of smoking on the pharmacokinetics and pharmacodynamics of clopidogrel have been the subject of numerous reports over the last decade ( Table 1) ( . The data on the association of smoking and platelet responsiveness to adenosine diphosphatereceptor blocking drugs like clopidogrel are inconsistent and controversial with studies variably showing: 1) no association; 2) a positive (higher on-treatment platelet reactivity in smokers) association; or 3) a negative (lower on-treatment platelet reactivity in smokers) association. Regarding the "negative association," meaning lower on-treatment platelet reactivity or greater platelet suppression, this unexpected benefit of an enhanced clopidogrel effect was termed the "new smoker's paradox." Although a potential mechanism for such surprising results of a heightened antiplatelet drug effect among active smokers might be related to the induction of CYP1A2 and CYP2B6 activity by smoking (15, 17, 25, 26) , which in turn may accelerate the in vivo bioactivation of clopidogrel, numerous confounders may have influenced the results of the respective studies.
In this issue of JACC: Cardiovascular Interventions, Kim et al. (24) performed extensive analyses to examine whether the postulated association of smoking and an enhanced clopidogrel response is maintained after adjusting for patients' hemoglobin levels. Focusing on hemoglobin levels seems intuitive, bearing in mind that active smokers are known to have higher hemoglobin levels (27) than nonsmokers and also considering that higher hemoglobin or hematocrit levels are associated with lower platelet P2Y 12 reaction units (PRU) when using the VerifyNow device (28) . Indeed, in a study cohort of 1, 314 clopidogrel-treated patients with recent percutaneous coronary intervention, the authors were able to confirm the known inverse correlation between PRU and hemoglobin levels (r ¼ À0.389; p < 0.001).
Although unadjusted analyses showed lower PRU levels in current smokers versus nonsmokers (as prior studies had observed), after adjusting for hemoglobin levels, no difference in PRU levels remained between non-smokers and current-smokers (224. has no relationships relevant to the contents of this paper to disclose. In column 4 "None" stands for no association found between smoking status and platelet reactivity (6 studies), "Positive" represents an associated higher on-treatment platelet reactivity in smokers (2 studies) and "Negative" stands for an associated lower on-treatment platelet reactivity in smokers (16 studies).
ADP ¼ adenosine diphosphate; AMI ¼ acute myocardial infarction; CAD ¼ coronary artery disease; HPR ¼ high on-treatment platelet reactivity; LTA ¼ light transmission aggregometry; NSTEMI ¼ non-ST segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; VASP-P ¼ vasodilator-stimulated phosphoprotein phosphorylation. 
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